Skip to main
SEPN

Septerna Inc (SEPN) Stock Forecast & Price Target

Septerna Inc (SEPN) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 57%
Buy 43%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Septerna is a promising clinical-stage biotechnology company utilizing its proprietary Native Complex Platform to unlock the potential of GPCR therapies. Not only has the company received a significant upfront payment of $195M from its partnership with Novo Nordisk, but it is also making progress on multiple discovery-stage programs in various therapeutic areas. With a strong focus on endocrinology, immunology, and inflammation, as well as metabolic disease, Septerna has the potential to deliver innovative and potentially game-changing treatments to patients in need.

Bears say

Septerna is facing several risks and challenges, including potential delays in advancing their pipeline of product candidates, setbacks in clinical trials, and partnership risks, specifically with Novo Nordisk. Their valuation is based on a discounted cash flow model, with a price objective of $35 per share, reflecting a total firm value of approximately $1.57 billion. However, there is a potential for lower-than-expected market penetration rates and long-term dilution risk, which could impact the achievement of this price target. Septerna's success may also hinge on securing approval for key candidates and generating significant sales in the highly competitive and lucrative GPCR therapy market.

Septerna Inc (SEPN) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 57% of analysts recommend a Strong Buy, 43% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Septerna Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Septerna Inc (SEPN) Forecast

Analysts have given Septerna Inc (SEPN) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Septerna Inc (SEPN) has a Strong Buy consensus rating as of May 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Septerna Inc (SEPN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.